论文部分内容阅读
目的探讨瑞舒伐他汀对慢性心力衰竭患者细胞因子及心功能的影响,为临床治疗提供依据。方法选取2012年3月—2013年6月收治的慢性心力衰竭患者60例,按照随机的原则分为对照组28例和观察组32例。对照组给予常规治疗(扩血管、抗心肌重构、抗血小板聚集以及强心、利尿等),观察组患者在对照组治疗的基础上加瑞舒伐他汀联合治疗。治疗前后对两组患者心功能变化情况进行统计,观察血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDI-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、红细胞沉降率(ESR)以及白细胞介素(IL-6)、血清超敏C-反应蛋白(hs-CRP)、血清肿瘤坏死因子-α(TNG-α)等指标变化情况。结果统计结果中观察组IL-6、hs-CRP、TNT-α、LDI-C等指标改善情况优于对照组,心功能各项指标均有所好转,对比差异有统计学意义(P<0.05)。结论在慢性心力衰竭患者临床治疗过程中,瑞舒伐他汀可有效降低血清炎性细胞因子和炎症标志物的水平,改善患者心功能,值得在临床上进行推广和应用。
Objective To investigate the effect of rosuvastatin on cytokines and cardiac function in patients with chronic heart failure and provide the basis for clinical treatment. Methods Sixty patients with chronic heart failure admitted from March 2012 to June 2013 were randomly divided into control group (n = 28) and observation group (n = 32). The control group was given routine treatment (vasodilator, anti-myocardial remodeling, anti-platelet aggregation and cardiac, diuretic, etc.). The observation group was treated with combination of rosuvastatin and control group on the basis of the control group. The changes of cardiac function in two groups before and after treatment were observed. The levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglyceride (TG) Erythrocyte sedimentation rate (ESR), interleukin (IL-6), serum hs-CRP and serum tumor necrosis factor-α (TNG-α) Results The statistical results showed that the improvement of IL-6, hs-CRP, TNT-α and LDI-C in observation group was better than that in control group, and the indexes of heart function improved. The difference was statistically significant (P <0.05 ). Conclusion In the clinical treatment of patients with chronic heart failure, rosuvastatin can effectively reduce serum levels of inflammatory cytokines and inflammatory markers and improve cardiac function, which is worth to be popularized and applied clinically.